An international congress organized by the Acıbadem healthcare network was held in Astana. Leading Turkish specialists shared their experience with the Kazakhstani medical community in the field of cellular technologies used in oncohematology.

CAR-T Technology

The key focus presented by Acıbadem experts was CAR-T cell therapy. This is a personalized treatment method based on the genetic “reprogramming” of a patient’s own immune cells. In the laboratory, the cells are modified to enable them to identify and selectively neutralize pathological, including cancerous, cells. This approach is considered one of the major breakthroughs in biomedicine over the past 10 years and is particularly relevant in cases where standard treatment methods are no longer effective.

Acıbadem is one of the few medical centers worldwide that has a full-cycle production of CAR-T therapies in its own Labcell laboratory. The clinic has accumulated many years of experience in applying this therapy to various types of blood cancers, including acute lymphoblastic leukemia, B-cell lymphoma, and multiple myeloma.

Kazakhstan has already launched a state program to introduce new cellular technologies. According to Alexander Shustov, Head of the Laboratory of Cellular Technologies at the National Center for Biotechnology, the first clinical application of CAR-T therapy in Kazakhstan is scheduled for 2026.